Inspirata, Inc.: Inspirata Announces Issuance of New U.S. Patent for its Digital Pathology System
Tampa, Florida, Jan. 07, 2021 (GLOBE NEWSWIRE) Cancer informatics and digital pathology provider Inspirata announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,878,025 for its Digital Pathology System. This patent joins Inspirata s portfolio of nine awarded patents and one patent pending.
Inspirata has been a thought leader in digital pathology for more than a decade, and the Digital Pathology System patent issuance is strong evidence of Inspirata s contribution to the foundation of the field. The issuance of this patent further validates our dedication and commitment to innovation and the advancement of digital pathology as a whole, said Dr. Mark Lloyd, Executive Vice President and Founder of Inspirata. This is an important milestone for Inspirata, and we look forward to continuing to expand our growing digital pathology port
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;